These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 29470610)

  • 1. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
    Zeukeng MJ; Seoane-Vazquez E; Bonnabry P
    Eur J Clin Pharmacol; 2018 Jun; 74(6):811-818. PubMed ID: 29470610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration.
    Rohr UP; Iovino M; Rudofsky L; Li Q; Juritz S; Gircys A; Wildner O; Bujar M; Bolte C; Dalla Torre di Sanguinetto S; Wolfer A
    Clin Transl Sci; 2023 Sep; 16(9):1569-1581. PubMed ID: 37408165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
    Kashoki M; Hanaizi Z; Yordanova S; Veselý R; Bouygues C; Llinares J; Kweder SL
    Clin Pharmacol Ther; 2020 Jan; 107(1):195-202. PubMed ID: 31306483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Oncologic Drugs from 2008 to 2023-Differences in Approval and Access between the United States, Europe and Brazil.
    Barreto RB; Izidoro AM; Miranda MHF
    Curr Oncol; 2024 Aug; 31(8):4443-4454. PubMed ID: 39195315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.
    Dörr P; Wadworth A; Wang T; McAuslane N; Liberti L
    Ther Innov Regul Sci; 2016 Nov; 50(6):734-742. PubMed ID: 30231740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision-Making at Swissmedic, the Swiss Regulatory Agency, with a Focus on (Neo)adjuvant Cancer Treatments.
    Zosso-Pavic M; Li Q; Juritz S; Gircys A; Wolfer A; Rohr UP
    Oncology; 2024; 102(10):907-912. PubMed ID: 38442691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory review of novel therapeutics--comparison of three regulatory agencies.
    Downing NS; Aminawung JA; Shah ND; Braunstein JB; Krumholz HM; Ross JS
    N Engl J Med; 2012 Jun; 366(24):2284-93. PubMed ID: 22591257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
    Vokinger KN; Kesselheim AS
    BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
    DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
    Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
    Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
    BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.
    Hwang TJ; Ross JS; Vokinger KN; Kesselheim AS
    BMJ; 2020 Oct; 371():m3434. PubMed ID: 33028575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian, European and United States new drug approval times now relatively similar.
    Rawson NSB
    Regul Toxicol Pharmacol; 2018 Jul; 96():121-126. PubMed ID: 29730446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?
    Bujar M; Ferragu S; McAuslane N; Liberti L; Kühler TC
    Clin Ther; 2021 May; 43(5):888-905. PubMed ID: 33883070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.